| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_452edf09f236371e61e3fd22a06ded78 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2011-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_378d1013f2e0cfef94156aa4f1fdc722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06a391a9037e9f862bb59b6d162c1956
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a67a0b66425033a90b959eadc54d34be |
| publicationDate |
2013-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2580324-A2 |
| titleOfInvention |
Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates |
| abstract |
Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative. |
| priorityDate |
2010-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |